Lung Cancer
A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
- Details
ClinicalTrials.gov ID:
NCT04613596
Diagnosis Type:
NA
USOR Number:
- Address
,
P: